Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

By Norum J.   Olsen J. A.   Wist E. A.   Lønning P. E.  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 153-164

Informa Healthcare

Access to resources Recommend Favorite

Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer

By Pusztai Lajos   Esteva Francisco  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 187-191

Informa Healthcare

Access to resources Recommend Favorite

Spotlight on Trastuzumab in Metastatic Breast Cancer Overexpressing HER2

By McKeage K.   Perry C.M.  

American Journal of Cancer, Vol. 1, Iss. 3, 2002-03 ,pp. : 217-221

Adis International

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial

By Purmonen Timo T.   Päänkäälääinen Emma   Turunen Juha H. O.   Asseburg Christian   Martikainen Janne A.  

Acta Oncologica, Vol. 50, Iss. 3, 2011-04 ,pp. : 344-352

Informa Healthcare

Access to resources Recommend Favorite